Harding M, Docherty V, Mackie R, Dorward A, Kaye S
Department of Medical Oncology, University of Glasgow, U.K.
Eur J Cancer Clin Oncol. 1989 May;25(5):785-8. doi: 10.1016/0277-5379(89)90121-1.
Seventy-seven patients were treated with oral mitozolomide to assess the activity of this drug in melanoma, lung and ovarian cancer. Partial responses were seen in five of 18 evaluable patients with small cell lung cancer (SCLC) and three of 20 with melanoma. No activity was apparent in non small cell lung or epithelial ovarian cancer. The major toxicity was myelosuppression which necessitated reduction in the initial dosage from 115 to 90 mg/m2. However, even at this dose level, unpredictable WHO grade 4 toxicity occurred in non-pretreated patients. Thrombocytopenia was more common than leucopenia and eight patients required platelet transfusion for spontaneous or tumour-related haemorrhage. Myelotoxicity was considered responsible for two deaths and was a significant contributory factor in a further three. Non-haematological toxicity was minor. Thus, despite demonstrable activity in SCLC and melanoma, unpredictable myelosuppression is likely to preclude further assessment in combination chemotherapy regimes in these tumours.
77例患者接受口服米托唑胺治疗，以评估该药物对黑色素瘤、肺癌和卵巢癌的疗效。18例可评估的小细胞肺癌（SCLC）患者中有5例出现部分缓解，20例黑色素瘤患者中有3例出现部分缓解。在非小细胞肺癌或上皮性卵巢癌中未观察到明显疗效。主要毒性为骨髓抑制，这使得初始剂量从115mg/m²降至90mg/m²。然而，即使在这个剂量水平，未经预处理的患者也出现了不可预测的WHO 4级毒性。血小板减少比白细胞减少更常见，8例患者因自发性或肿瘤相关性出血需要输注血小板。骨髓毒性被认为导致了2例死亡，另外3例死亡中骨髓毒性也是一个重要因素。非血液学毒性较小。因此，尽管米托唑胺在SCLC和黑色素瘤中显示出一定疗效，但不可预测的骨髓抑制可能会妨碍其在这些肿瘤联合化疗方案中的进一步评估。
